Peter Greenleaf - 06 Mar 2024 Form 4 Insider Report for Aurinia Pharmaceuticals Inc. (AUPH)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: AUPH
Reported as of: 06 Mar 2024
Net transaction value: -$711,094
SEC form: 4
Accepted by SEC: 07 Mar 2024, 16:46:19 UTC
Prior SEC filing: 22 Feb 2024
Next SEC filing: 04 Mar 2025
Source filing: View source filing
Reporting owner signature: /s/ Peter S. Greenleaf

Key filing fact

Peter Greenleaf filed Form 4 for Aurinia Pharmaceuticals Inc. (AUPH) on 07 Mar 2024.

Key facts

This page summarizes Peter Greenleaf's Form 4 filing for Aurinia Pharmaceuticals Inc. (AUPH).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 07 Mar 2024, 16:46.

Change

Previous filing in this sequence was filed on 22 Feb 2024.
Current net transaction value: -$711,094.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AUPH transaction

Common Stock

Sale

Transaction value: $711,094
Shares: -126,981
Change %: -7.7%
Price: $5.60
Shares after: 1,522,114
Date: 06 Mar 2024
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of Restricted Stock Units related to the March 2, 2022 and March 2, 2023 grants.

Footnote F2

The price in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.475 to $5.755, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.